- •Compounded versions are cheaper and currently legal for TRT and several GLP-1s, but the FDA peptide framework is in active flux. What's legally accessible in 2026 is not what was legally accessible in 2024.
- •Telemedicine clinics collapsed pricing but vary widely on lab discipline. A cheap script with no labs is the most expensive version of any protocol.
- •Country comparisons matter. Canada and the UK gate access through physicians with reasonable monitoring. The US is split between insurance-covered branded and cash-pay compounded. Some markets are more permissive but rarely include monitoring.
- •Insurance vs cash-pay isn't the only axis. What you actually pay = drug + labs + clinic visits + ancillary supplies. The cheapest drug is often the most expensive total spend.
Overview
Access to TRT, GLP-1s, and peptides changed more between 2023 and 2026 than in the prior decade. Compounded versions of GLP-1s went from grey-area to mainstream and are now in active regulatory flux. The FDA's peptide framework moved roughly two dozen popular peptides into Category 2 status, then 12 of them came off the list in April 2026 after sponsors withdrew nominations, and a July 2026 advisory committee is scheduled to consider whether to formally clear the contested core (BPC-157, TB-500, MOTS-c, and others). Static guides are wrong within weeks.
This page is the cross-cut for the country, clinic, and pricing questions across all three pillars. For the protocol-specific context:
Pricing across protocols
How much do TRT, GLP-1, and peptide protocols cost in 2026?
Approximate US cash prices (compounded, monthly, before labs and clinic fees) as of mid-2026:
| Protocol | Compounded cash | Branded with insurance | Branded cash |
|---|---|---|---|
| TRT (cypionate + supplies) | $40–120 | $20–80 copay | $200–400 |
| Semaglutide | $150–300 | $25–500 (highly plan-dependent) | $1,000+ |
| Tirzepatide | $200–450 | $25–500 (plan-dependent) | $1,000+ |
| Retatrutide | research-chem grey market only | not commercial | not commercial |
| BPC-157, GH peptides | $30–150 (when accessible) | n/a | n/a |
These prices move quarterly. The bigger budget question is the totality of spend: a $40 TRT script with no labs, no clinic follow-up, and no hematocrit management is a worse deal than a $120 telemedicine clinic that includes quarterly labs in the membership.
The 2026 regulatory state
What changed for compounded GLP-1s and peptide compounding in 2026?
The 2026 regulatory state at a glance:
- TRT: stable. Schedule III in the US, controlled in most jurisdictions, prescribed off-label and on-label depending on indication. Compounded cypionate is widely available via 503A pharmacies. No major regulatory threat in the near term.
- GLP-1s (compounded): in active flux. The FDA's December 2024 declaration that semaglutide and tirzepatide were no longer in shortage[1] triggered enforcement actions against several large compounders. Compounded versions remain accessible through specific pathways (clinical-need exception, personalized dosing) but the broad consumer-grade compounding model is constrained. Expect further consolidation through 2026.
- Peptides: the most contested category. The FDA placed 19 peptides into Category 2 in 2023[2]; January 2025 finalization confirmed the framework but didn't add new compounds. RFK's February 2026 announcement signaled a partial reversal, and the FDA confirmed 12 of those peptides came off Category 2 in April 2026 after sponsors withdrew nominations[3]. A July 2026 advisory committee is reviewing whether to add the contested core (BPC-157, TB-500, MOTS-c, GHK-Cu, and others) to the 503A bulks list[4]. The practical access question changes depending on which compound and which sourcing pathway.
What this means for users: lock in a relationship with a clinic that can adapt, both to dose changes and to compound substitutions if a specific compound becomes inaccessible. A clinic that only carries one compound is one rule change from being unable to refill you.
Access & cost by country
Access routes and pricing differ sharply by country. Here are the major English-speaking markets plus Germany — tap a country for the full guide. Figures are approximate (mid-2026) and exclude labs and clinic fees.
| Country | TRT | GLP-1 | Peptides |
|---|---|---|---|
| United States | Insurance-covered branded or cash-pay compounded | Insurance (criteria) or cash / compounded | Compounding in active FDA flux |
| United Kingdom → | NHS if T<8 nmol/L, else private £75–175/mo | NHS (SWMS) or private £99–340/mo | Not licensed medicines |
| Australia → | PBS if medically low, else private | Ozempic PBS (T2D); Mounjaro private ~A$350–400 | Tightly scheduled (TGA) |
| Canada → | Private / insurance; ~C$35–130/mo | Private; generic semaglutide ~C$88–120/mo | Rx-only approved; grey research market |
| Ireland → | Private clinics; DPS €80/mo cap applies | Diabetes via LTI; weight-loss private ~€130–340 | HPRA-regulated; not approved |
| Germany → Deutsch | GKV if medically indicated | Ozempic GKV (T2D); Wegovy self-pay ~€250–350 | Not approved |
General guidance, not medical or legal advice. Eligibility thresholds and prices change quickly — verify with a local clinician and official sources. A full German-language guide is coming with OptiPin's German site.
Country & protocol guides
Go deeper by country or by protocol. The country guides cover TRT, GLP-1, and peptide access and cost in that market; the pillar guides cover the clinical detail.
By country
- TRT, GLP-1 & peptide access in the United Kingdom
- TRT, GLP-1 & peptide access in Australia
- TRT, GLP-1 & peptide access in Canada
- TRT, GLP-1 & peptide access in Ireland
- TRT, GLP-1 & Peptide: Zugang & Kosten in Deutschland (Deutsch)
By protocol
In the OptiPin app
OptiPin's vial inventory tracks per-compound supply across all three protocols, with discard alerts and reorder reminders set per compound (TRT vials are stable for months; reconstituted GLP-1s and peptides have shorter windows). The cost-per-dose calculator factors in vial size, BAC water dilution, dose, and discard windows so the actual price you pay per shot is visible, useful when comparing a $300 compounded vial that lasts six months to a $150 vial that lasts six weeks. For users running cross-protocol stacks (TRT + GLP-1, TRT + peptides, all three), the inventory view is the only place the full monthly cost is reconciled across compounds without manual spreadsheet work.
Sources
- [1]FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (FDA Drug Alerts and Statements) (2024)
- [2]Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (FDA Human Drug Compounding)
- [3]Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (FDA, updated April 22, 2026) (2026)
- [4]July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (FDA) (2026)
Frequently Asked Questions
Is compounded GLP-1 still legal in 2026?
It depends on the pathway. After the FDA declared semaglutide and tirzepatide no longer in shortage (December 2024), the broad compounding-for-the-shortage pathway closed. Personalized-prescription compounding (custom dose, combined formulations) and clinical-need exceptions remain. Several large telemedicine compounders restructured to operate within those exceptions; others stopped. The legal answer for any specific clinic is whether their compounding pathway fits one of the surviving exceptions.
Should I import TRT or peptides from outside the US?
Generally not. US Customs seizures of personal-import androgens and peptides are routine, the legal exposure is real (Schedule III for TRT, varying for peptides), and the quality control on grey-market international sourcing is unverifiable. Where international access matters, medical tourism for users without US insurance, Canada, the UK, and Ireland have legitimate gated pathways. The Philippines and several other markets are more permissive but rarely include monitoring.
How do I evaluate a telemedicine clinic?
Three questions cut through marketing: (1) what bloodwork is included in the membership, and at what cadence; (2) what's the compounding pharmacy and can you see their accreditation; (3) what happens when you need a dose change, schedule change, or compound switch, same provider, asynchronous message turnaround, or do you start over. The first question alone separates serious clinics from refill mills.
Track Your Protocol in OptiPin
Log doses, forecast hormone and compound levels, rotate sites, daily symptom check-ins, and lab tracking, all private and on-device.
Download on the App Store